Expression of p-VEGFR2 on tumor cells was significantly reduced after cycle one chemotherapy in the Bevacizumab Cohort for both Y951 and Y996, although there appears to be a rebound in p-VEGFR2 after cycle 4 chemotherapy (mean H score [Y951] 55.25 ± 41.15, 32.00 ± 38.60, 50.67 ± 41.82 for baseline, post-C1 and post-C4; p = 0.008 for baseline vs post-C1, p = 0.819 for baseline vs post-C4; mean H score [Y996] 27.50 ± 38.54, 4.75 ± 9.79, 7.33 ± 10.83 for baseline, post-C1 and post-C4; p = 0.004 for baseline vs post-C1, p = 0.124 for baseline vs post-C4) (Fig. 2g, h). The gene discussed is KDR; the disease is neoplasm.